Bipolar I disorder is primarily defined by manic or mixed episodes that last for at least 7 days, or very severe manic symptoms needing immediate hospital care. The patient also has depressive episodes which may last for at least 2 weeks.
Bipolar II disorder is usually misdiagnosed. It is characterized by occurence of ≥1 major depressive episodes with at least 1 hypomanic episode.
Cyclothymic disorder or cyclothymia is a mild form of bipolar disorder. Patients have episodes of hypomania alternating with mild depression that lasts for 2 years.
Rapid-cycling bipolar disorder patients have ≥4 episodes of major depression, mania, hypomania or mixed symptoms within a year.
Statin appears to provide lipid-lowering benefits in patients with severe mental illness such as bipolar disorder or schizophrenia, and this effect is of similar magnitude to that observed in the general population, according to a study. However, the drug does not yield reductions in cardiovascular (CV) events or all-cause mortality.
Maintenance treatment with lithium, rather than quetiapine, may induce greater improvements in depression, mania and psychotic symptoms over 12 months in patients treated with a combination of lithium and quetiapine for a first manic episode with psychotic features, according to the results of a trial.
A study suggests that the prevalence of overweight and obesity (OW/OB) in adolescents with and without bipolar disorder (BD) is correlated with proxies for depression severity such suicide attempts and hospitalization.
Results of the Course and Outcome of Bipolar Youth study show that bipolar disorder (BD) in youth with high-functioning autism spectrum disorder (ASD) present with typical BD mood symptoms at an earlier onset, with mixed symptom presentation and additive functional impairments.
Vortioxetine 5-20 mg/day lessens depression and anxiety severity in patients with major depressive disorder (MDD) and high levels of anxiety, as observed in a meta-analysis of 10 randomised, placebo-controlled, 6/8-week trials.